Avara CEO Timothy Tyson said the acquisition will expand the contract development and manufacturing organisation’s (CDMO) offering.
“This key acquisition is another important component of our strategic plan that further expands our services,” said Tyson.
Secondary manufacturing services include granulation, blending, coating, encapsulation, compression and drying of tablets and capsules.
AstraZeneca told us 130 of its employees will be transferred to Avara.
Buying power
This is the third manufacturing facility Avara has purchased from a large-scale pharmaceutical firm in just over a year.
In September 2016, the company announced it would buy AstraZeneca’s Avlon, England-based active pharmaceutical ingredient (API) plant.
In August of this year, Avara agreed to purchase a sterile drug manufacturing facility from Pfizer in Liscate, Italy.
Avara now has sites in France, the US, the UK, Ireland, Italy and Puerto Rico.